Developmental Therapeutics Research Program

发育治疗研究计划

基本信息

批准号：
9923038
负责人：
GLENN LIU
金额：
$ 10.35万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9923038
关键词：
Advanced Malignant Neoplasm Antibodies Applied Research Award Basic Science Biological Biological Assay Biological Markers Cancer Center Cancer Patient Childhood Clinic Clinical Clinical Research Clinical Trials Clinical Trials Network Collaborations Comprehensive Cancer Center Development Developmental Therapeutics Program Direct Costs Disease Dreams Drug Targeting Estrogen receptor positive Funding Goals Head Cancer Hematologic Neoplasms Image Immunotherapy Individual Industry Collaboration Innovative Therapy Intervention Investigational Therapies Laboratories Lead Malignant Neoplasms Malignant neoplasm of prostate Mission Molecular Molecular Target Monitor National Clinical Trials Network Neck Cancer Neoplasm Circulating Cells New Agents Outcome Paper Pathway interactions Patient-Focused Outcomes Patients Peer Review Peptides Pharmaceutical Chemistry Pharmaceutical Preparations Phase Phase I Clinical Trials Preparation Publications Publishing Rain Reproduction spores Research Research Personnel Resource Sharing Schools Science Services Signal Transduction Solid Neoplasm Source Strategic Planning Therapeutic Therapeutic Agents Therapeutic Human Experimentation Time Translating Translational Research Translations United States National Institutes of Health Work anticancer research base biomarker development biomarker discovery cancer biomarkers cancer cell cancer clinical trial cancer therapy clinical translation college data resource drug discovery early phase clinical trial effective therapy first-in-human improved interdisciplinary approach member new therapeutic target novel novel therapeutics peer pre-clinical predictive test programs research and development resistance mechanism response small molecule targeted agent targeted cancer therapy therapeutic biomarker therapeutic development treatment strategy tumor immunology

项目摘要

UWCCC Developmental Therapeutics (DT) Program Summary Co-Leaders: Glenn Liu, Shigeki Miyamoto, and Jing Zhang PROJECT SUMMARY/ABSTRACT The mission of the UW Carbone Cancer Center (UWCCC) Developmental Therapeutics (DT) Program is to improve cancer patient outcomes by discovering new targets, developing therapeutic agents and biomarkers, and translating this research into early phase clinical trials. The DT Program provides the translational direction not only for DT members, but for other programs within the UWCCC (e.g. GEM, VR, TM). Clinical trial data and resources inform our understanding of response and resistance mechanisms and enable the identification of new therapeutic targets and treatment strategies to improve clinical outcomes. The DT Program has 59 core members, representing 18 departments and 5 different schools/colleges. Research impacts of DT members are evidenced by research awards totaling over $22.5M in annual direct cost of peer-reviewed and non-peer reviewed funding (including $3.45M NCI, $6.2M cancer-related other NIH agencies, $4.97M peer-reviewed non-NIH sources, $7.9M non-peer reviewed funding) and a significant number of publications (1228 publications, 18% of which result from intra-programmatic collaboration and 24% from inter-programmatic work). A key component of the new UWCCC Strategic Operating Plan is to further strengthen and develop Innovative Therapies and Cancer Biomarkers. Consistent with this strategic goal, the thematic aims of the DT Program are to: 1) discover new molecular targets for cancer therapy; 2) develop new agents and biomarkers; and 3) translate new therapies and biomarkers into clinical trials. To achieve this goal, it is critical to have a very strong program that discovers, develops, and translates novel interventions and biomarkers. To this end, members of the DT Program come from basic science, applied science, and clinical departments. This program has expertise ranging from basic discovery (molecular pathways and targets), to development (drugs/assays/biomarkers), to early clinical translation application (Phase 1 clinical trials). Translational and clinical research DT program members apply intra- and inter-programmatic research discoveries in clinical trials, performing the majority of first-in-human or early phase clinical trials, while individual disease-specific research teams (Disease Oriented Teams) focus primarily on phase 2 and 3 studies. DT members lead or participate in all clinical research groups facilitating both translational and reverse-translational opportunities.

UWCCC 发育治疗 (DT) 计划摘要联合领导者：Glenn Liu、Shigeki Miyamoto 和 Jing Zhang 项目概要/摘要威斯康星大学卡本癌症中心 (UWCCC) 发育治疗 (DT) 计划的使命是通过发现新靶点、开发治疗药物和生物标志物来改善癌症患者的治疗效果，并将这项研究转化为早期临床试验。 DT 计划提供转化方向不仅适用于 DT 会员，也适用于 UWCCC 内的其他项目（例如 GEM、VR、TM）。临床试验数据和资源让我们了解应对和抵抗机制，并能够识别新的治疗目标和治疗策略以改善临床结果。 DT计划有59个核心成员，代表 18 个部门和 5 个不同的学校/学院。 DT 成员的研究影响同行评审和非同行年度直接成本总计超过 2250 万美元的研究奖项证明了这一点审查资金（包括 345 万美元 NCI、620 万美元癌症相关其他 NIH 机构、497 万美元同行评审非 NIH 来源、790 万美元非同行评审资金）和大量出版物（1228 出版物，其中 18% 来自项目内合作，24% 来自项目间合作工作）。新的 UWCCC 战略运营计划的一个关键组成部分是进一步加强和发展创新疗法和癌症生物标志物。与这一战略目标相一致， DT计划旨在：1）发现癌症治疗的新分子靶点； 2）开发新的代理和生物标志物； 3）将新疗法和生物标志物转化为临床试验。要实现这一目标，关键是拥有一个非常强大的计划来发现、开发和转化新颖的干预措施和生物标志物。到为此，DT计划的成员来自基础科学、应用科学和临床部门。该计划拥有从基本发现（分子途径和靶标）到开发的专业知识（药物/测定/生物标志物），到早期临床转化应用（一期临床试验）。翻译和临床研究 DT 计划成员将计划内和计划间的研究发现应用于临床试验，进行大部分首次人体或早期临床试验，同时针对个别疾病研究团队（疾病导向团队）主要关注第 2 阶段和第 3 阶段研究。 DT 成员领导或参与所有临床研究小组，促进转化和逆翻译机会。